2018
Clinical Microbiology reviews
Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery StrategiesDownload article here (.pdf)
News & Publications
2017
Case Reports in Dermatology
Successful Treatment of Chronic Staphylococcus aureus-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 CasesDownload article here (.pdf)
2017
Article
The IgG response against Staphylococcus aureus is associated with severe atopic dermatitis in children.Download article here (.pdf)
2017
Totté et al. Trials
Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial)Download article here (.pdf)
2017
Article
The prevalence of antibody responses against Staphylococcus aureus antigens in patients with atopic dermatitis: a systematic review and meta-analysisDownload article here (.pdf)
2016
Article
A systematic review and meta-analysis on Staphylococcus aureus carriage in psoriasis, acne and rosaceaDownload article here (.pdf)
2016
British Journal of Dermatology
Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysisDownload article here (.pdf)
May 4th 2015
Endolysin Technology Presents an Antibiotic Alternative with Broad Applicability
Endolysin technology targets unwanted bacteria, including resistant strains.View this article at PharmTech.com
April 29th 2015
New data presented at Royal Society of Medicine shows broad applicability of antibiotic alternative
Click here to watch the presentation (video)Click here to view (PDF)
January 29th 2015
Micreos invited to speak at the Royal Society of Medicine Spring Summit
Micreos invited to speak at the Royal Society of Medicine Spring Summit 2015 in London, April 18.Click here for more information about the event
November 13th 2014
Newsweek
Revolutionary New Antibiotic Alternative Could Save the World From Superbug 'Apocalypse'Download article here
November 6th 2014
TIME magazine
Scientists develop drug to replace antibiotics.Download article here
November 12th 2014
The Pharmaceutical Journal
New bactericidal enzyme solution could help the fight against MRSA infection.Download article here (.pdf)
November 7th 2014
The Pharma Letter
Micreos' Staphefekt is the world's first bacteria-killing enzyme for human use in MRSA.Download article here (.pdf)
November 6th 2014
The Times
Scientists create drug to replace antibiotics.Download article here (.pdf)
November 6th 2014
Sky Video Coverage
Scientists Develop Alternative To Antibiotics: A new drug based on a naturally-occurring enzyme can fight superbugs which have evolved to resist antibiotics.Click here to view
November 6th 2014
Forbes
Our first weapon against superbug MRSA.Download article here
November 12th 2014
BNR Health (Business News Radio) interviews Mark Offerhaus
BNR interviews Micreos' CEO Mark Offerhaus on Staphefekt, world's first bacteria-killing enzyme for human use targeting MRSA and Staphylococcus aureus-bacteria causing skin infections.Click here to listen (Dutch)
November 7th 2014
NPO Radio 1, The Netherlands
Interview with clinical microbiologist Bjorn Herpers and Micreos' CEO Mark Offerhaus on Staphefekt, world's first product targeting MRSA on the skin.Click here to listen (Dutch)
Press release, November 5, 2014
Dutch biotech Micreos launches first bacteria-killing enzyme for human use against MRSA
Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA).Download article here (.pdf)
EuroSciCon
'Antibiotic Alternatives for the New Millennium Conference', November 5-7, 2014, London, UK
Specific lysis of Staphylococcus aureus by the endolysin Staphefekt™ SA.100: In vitro studies and human case series - Dr. B.L. Herpers.Download article here (.pdf)
B.L. Herpers et al., 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Staphefekt™ effectively kills MRSA & MSSA without disturbing normal skin flora
Lysis of S. aureus by Staphefekt SA.100™ is dose dependent, specific and efficient. Staphefekt™ is equally effective in killing both methicillin susceptible and resistant strains, without disturbing the normal skin flora.Download article here (.pdf)
Allen, H.B. et al. 2014, JAMA Dermatology
The Presence and Impact of Biofilm-Producing Staphylococci in Atopic Dermatitis
Atopic dermatitis lesions are strongly colonized by biofilm producing Staphylococci, which occlude sweat ducts...This would lead to itching, scratching, and the production of a rash.Download article here (.pdf)
Oh et al. 2013, Genome Res.
The altered landscape of the human skin microbiome in patients with primary immunodeficiences.
S. aureus was most significantly correlated with disease severity. However, it is increasingly clear that microbial pathogens, such as S. aureus, which can asymptomatically colonize human hosts, may only be disease-associated in the context of their microbial communities and host factors.Download article here (.pdf)
Nakamura et al. 2013, Nature
Staphylococcus δ-toxin induces allergic skin disease activating mast cells.
These studies identify δ-toxin as a potent inducer of mast cell degranulation and suggest a mechanistic link between S. aureus colonization and allergic skin disease.Download article here (.pdf)
Chiu et al. 2013, Nature
Bacteria activate sensory neurons that modulate pain and inflammation.
Our data reveal an unsuspected mechanism for pain induction during bacterial infection: Direct activation of sensory neurons (nociceptors) by bacteria is probably a major mechanism leading to pain, especially early in S. aureus infection during active pathogen expansion.Download article here (.pdf)
Gravitz, L. 2012, Nature Medicine
Turning a new phage.
The idea of using bacteria-fighting viruses as a weapon against hard-to-treat infections is making a surprising comeback. Researchers and companies are now tweaking and deconstructing these bacteria killers in an effort to develop a new arsenal against antibiotic-resistant superbugs.Download article here (.pdf)
Fluit A.C., Marm van S., et al. 2012, ICAAC
Killing and lysis of S. aureus and other staphylococci by an endolysin.
Efficient killing of different S. aureus strains is obtained bij using Staphefekt™ SA.100. Staphylococcal species belonging to the normal human commensal flora as well as other species are not affected.Download article here (.pdf)
Adejuwon A.O., Ajayi A.A. 2010, IJMMS
Antibiotics resistance and susceptibility pattern of a strain of Staphylococus aureus associated with acne.
Investigation showed the presence of Staphylococcus aureus in pus from acne.Download article here (.pdf)
Huang J.T., Abrams M., et al. 2009, Pediatrics
Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity
S. aureus skin infections in atopic dermatitis are linked to the high rates of S. aureus colonization in the atopic dermatitis population. Treatment of S. aureus colonization in atopic dermatitis decreases disease severity.Download article here (.pdf)
Leung D.Y.M. 2008, Acta Derm Venereol.
The role of Staphylococcus aureus in atopic eczema.
Colonization and infection with S. aureus contributes to the severity of atopic eczema, inducing skin inflammation, leading in turn to sustained S. aureus colonization and infection.Download article here (.pdf)
Gong J.Q., Lin L., et al. 2006, British Journal of Dermatology
Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial.
A correlation between the severity of the eczema and colonization with S. aureus has been demonstrated, and it has been determined that bacterial colonization is an important factor aggravating skin lesions.Download article here (.pdf)
